Quantum Biopharma Ltd.
No SEC Form 4 filings for $QNTM in the last 30 days.
See all $QNTM insider activity →Quantum BioPharma (QNTM) received FDA approval to advance Lucid-MS into phase 2 trials. The company's MS treatment showed a favorable safety profile in phase 1. This approval allows patient recruitment and clinical testing to begin.
Quantum BioPharma (QNTM) received a Buy rating and $8 price target from Rodman & Renshaw, more than double its current share price. The rating is based on LUCID-MS, an experimental oral therapy for progressive multiple sclerosis, which targets the PAD2 enzyme. The FDA cleared the drug for a Phase 2 trial, with enrollment expected to begin in 2027 and results projected for 2029. The company has $9.5 million in cash but may need to raise additional capital for the trial. Quantum also holds a 19.5%
Rodman & Renshaw initiated coverage on Quantum BioPharma (QNTM) with a BUY rating and a $8 price target. The research report was unpaid, with no fees from Quantum BioPharma. Quantum BioPharma focuses on biotech solutions for neurodegenerative and metabolic disorders.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning QNTM (Quantum Biopharma Ltd.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent QNTM coverage spans regulation, financial news and technology.
Positive regulatory milestone likely to boost stock sentiment.
Analyst upgrade and aggressive price target could drive short-term buying pressure.
Analyst initiation may lift the stock and set a new valuation baseline.
The clearance could drive QNTM stock higher as investors price in potential breakthrough therapy and market expansion.
FDA clearance is a material catalyst for a biotech with limited pipeline.
AlphAI scores every news story that mentions QNTM with an AI model for sentiment and relevance, and aggregates insider trades from Quantum Biopharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Quantum BioPharma (QNTM) received FDA approval to advance Lucid-MS into phase 2 trials. The company's MS treatment showed a favorable safety profile in phase 1. This approval allows patient recruitment and clinical testing to begin.
1 min readQuantum BioPharma (QNTM) received a Buy rating and $8 price target from Rodman & Renshaw, more than double its current share price. The rating is based on LUCID-MS, an experimental oral therapy for progressive multiple sclerosis, which targets the PAD2 enzyme. The FDA cleared the drug for a Phase 2 trial, with enrollment expected to begin in 2027 and results projected for 2029. The company has $9.5 million in cash but may need to raise additional capital for the trial. Quantum also holds a 19.5%
2 min readRodman & Renshaw initiated coverage on Quantum BioPharma (QNTM) with a BUY rating and a $8 price target. The research report was unpaid, with no fees from Quantum BioPharma. Quantum BioPharma focuses on biotech solutions for neurodegenerative and metabolic disorders.
1 min readQuantum BioPharma (QNTM) received FDA clearance for a phase 2 trial of Lucid-MS, a novel MS treatment targeting demyelination. The trial is historic as it tests a new mechanism never before used in MS patients. The company aims to shield and potentially rebuild the myelin sheath, addressing a significant unmet medical need. Analysts have given the company a fresh buy rating. The global MS therapeutics market is projected to reach $38.62 billion by 2030.
3 min readOpus Genetics (IRD) rose 27% after positive clinical trial data. Quantum (QNTM) gained 10% with FDA Phase 2 trial clearance. Pulse Biosciences (PLSE) surged 15% without specific news. Decoy Therapeutics (DCOY) and ONWARD Medical (ONWD.BR) also traded higher on updates.
3 min readQuantum BioPharma (QNTM) received FDA approval for a phase 2 trial of Lucid-MS, a drug targeting myelin repair in MS patients. The company aims to address unmet needs in MS treatment, differentiating itself from competitors like Sanofi (SNY), Roche (RHHBY), and Biogen (BIIB). Analysts issued a buy rating following the FDA clearance, marking a potential breakthrough in MS therapy.
2 min readQuantum BioPharma (TSX: QNTM) shares fell 5.75% on September 3, 2026, despite FDA clearance for its Lucid-MS program to advance to Phase 2 trials. The decline reflects investor caution about clinical execution risks, regulatory uncertainty, and funding pressures. The company's value hinges on successful development and commercialization of its pipeline, with Phase 2 trials being a key catalyst.
5 min readQuantum BioPharma (NASDAQ: QNTM) plans to delist its Class B shares from the Canadian Securities Exchange (CSE), citing low trading volume. The company will continue trading on Nasdaq, Frankfurt Stock Exchange, and Upstream. Quantum expects the move to reduce costs and improve liquidity. The delisting is subject to CSE approval, expected by September 4, 2026.
2 min readQuantum BioPharma's shares fell 4.44% on August 26, 2026, despite FDA clearance for a Phase 2 trial of its lead drug, Lucid-MS. The decline reflects clinical risks, profit-taking, and broader biotech volatility. The company's revenue depends on successful drug development, with no near-term earnings visibility. Investors focus on clinical progress and potential partnerships.
3 min readQuantum BioPharma (TSX: QNTM) shares fell 4.26% on August 25, 2026, despite FDA clearance for its Lucid-MS program to advance to Phase Two trials. The decline reflects investor uncertainty around clinical execution, funding, and commercialization risks. The company's value is tied to its development-stage biotech assets, with limited earnings visibility and high volatility.
3 min read
